Nestlé Health Science further invests in Aimmune Therapeutics

Isotonic

Nestlé Health Science (NHSc) today announced that it will make a further equity investment of USD 200 million in Aimmune Therapeutics, a California-based biopharmaceutical company developing and commercializing treatment for potentially life-threatening food allergies.

—————
TRANSCOM ISPFree Sigma HSE Email
Level 6 Domain Names are FREE – Register Now.

Related Posts